Literature DB >> 26980502

Profiling the human immune response to Mycobacterium tuberculosis by human cytokine array.

Tao Chen1, Zhenyan Li2, Li Yu3, Haicheng Li1, Jinfei Lin1, Huixin Guo1, Wei Wang4, Liang Chen1, Xianen Zhang5, Yunxia Wang6, Yuhui Chen1, Qinghua Liao5, Yaoju Tan7, Yang Shu1, Wenyan Huang6, Changhui Cai8, Zhongjing Zhou9, Meiling Yu9, Guozhou Li10, Lin Zhou11, Qiu Zhong12, Lijun Bi13, Meigui Zhao14, Lina Guo15, Jie Zhou16.   

Abstract

OBJECT: Tuberculosis (TB) continues to be one of the most serious infectious diseases in the world, however, no effective biomarkers can be used for rapid screening of latent tuberculosis infection (LTBI) and active TB. In this study, serum cytokines were screened and tested as potential biomarker for TB diagnosis.
METHOD: Cytokine array was used to track the cytokine profile and its dynamic change after TB infection. The different expressions of cytokines were confirmed by ELISA assay. ROC curve analyses were used to evaluate the efficacy of a cytokine or cytokine combination for diagnosis.
RESULTS: Eotaxin-2, ICAM-1, MCSF, IL-12p70, and IL-11 were significantly higher in the LTBI individuals. I-309, MIG, Eotaxin-2, IL-8, ICAM-1, IL-6sR, and Eotaxin were significantly higher in active TB patients. ROC curve analyses gave AUCs of 0.843, 0.898, and 0.888 for I-309, MIG, and IL-8, respectively, and 0.894 for the combination panel in active TB diagnosis. IFN-γ/IL-4 and IL-2/TNF-α ratios exhibit dynamic changes in the healthy control and LTBI to different stages of active TB.
CONCLUSIONS: Serum cytokines, including I-309 and MIG, IL-8, Extoxin-2, ICAM-1 and combinations of cytokines, including IFN-γ/IL-4 and IL-2/TNF-α, can be used as serum biomarkers for LTBI and active TB screening, thus indicating prospective clinical applications.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  I-309; IFN-γ/IL-4; IL-2/TNF-α; IL-8; MIG; Tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 26980502     DOI: 10.1016/j.tube.2015.12.007

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  13 in total

1.  Cytokine Biosignature of Active and Latent Mycobacterium Tuberculosis Infection in Children.

Authors:  Magdalena Druszczynska; Michal Seweryn; Sebastian Wawrocki; Magdalena Kowalewska-Pietrzak; Anna Pankowska; Wieslawa Rudnicka
Journal:  Pathogens       Date:  2021-04-24

2.  Diagnostic Potential of Novel Salivary Host Biomarkers as Candidates for the Immunological Diagnosis of Tuberculosis Disease and Monitoring of Tuberculosis Treatment Response.

Authors:  Ruschca Jacobs; Elizna Maasdorp; Stephanus Malherbe; Andre G Loxton; Kim Stanley; Gian van der Spuy; Gerhard Walzl; Novel N Chegou
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

3.  Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response.

Authors:  Ruschca Jacobs; Stephanus Malherbe; Andre G Loxton; Kim Stanley; Gian van der Spuy; Gerhard Walzl; Novel N Chegou
Journal:  Oncotarget       Date:  2016-09-06

4.  Application of ImmunoScore Model for the Differentiation between Active Tuberculosis and Latent Tuberculosis Infection as Well as Monitoring Anti-tuberculosis Therapy.

Authors:  Yu Zhou; Juan Du; Hong-Yan Hou; Yan-Fang Lu; Jing Yu; Li-Yan Mao; Feng Wang; Zi-Yong Sun
Journal:  Front Cell Infect Microbiol       Date:  2017-10-30       Impact factor: 5.293

5.  Severe Tuberculosis in Humans Correlates Best with Neutrophil Abundance and Lymphocyte Deficiency and Does Not Correlate with Antigen-Specific CD4 T-Cell Response.

Authors:  Alexander V Panteleev; Irina Yu Nikitina; Irina A Burmistrova; George A Kosmiadi; Tatyana V Radaeva; Rasul B Amansahedov; Pavel V Sadikov; Yana V Serdyuk; Elena E Larionova; Tatef R Bagdasarian; Larisa N Chernousova; Vitaly V Ganusov; Irina V Lyadova
Journal:  Front Immunol       Date:  2017-08-21       Impact factor: 7.561

6.  Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.

Authors:  Sasha E Larsen; Susan L Baldwin; Mark T Orr; Valerie A Reese; Tiffany Pecor; Brian Granger; Natasha Dubois Cauwelaert; Brendan K Podell; Rhea N Coler
Journal:  Vaccines (Basel)       Date:  2018-05-24

7.  Tuberculosis patients display a high proportion of CD8+ T cells with a high cytotoxic potential.

Authors:  Leslie Chávez-Galán; Jhacqueline Illescas-Eugenio; Magaly Alvarez-Sekely; Renata Baez-Saldaña; Raúl Chávez; Ricardo Lascurain
Journal:  Microbiol Immunol       Date:  2019-07-26       Impact factor: 1.955

8.  Diagnostic performance of blood inflammatory markers for tuberculosis screening in people living with HIV.

Authors:  Katherine Farr; Resmi Ravindran; Luke Strnad; Emily Chang; Lelia H Chaisson; Christina Yoon; William Worodria; Alfred Andama; Irene Ayakaka; Priscilla Bbosa Nalwanga; Patrick Byanyima; Nelson Kalema; Sylvia Kaswabuli; Winceslaus Katagira; Kyomugisha Denise Aman; Emmanuel Musisi; Nuwagaba Wallen Tumwine; Ingvar Sanyu; Robert Ssebunya; J Lucian Davis; Laurence Huang; Imran H Khan; Adithya Cattamanchi
Journal:  PLoS One       Date:  2018-10-23       Impact factor: 3.240

9.  Diagnostic accuracy of interferon-gamma-induced protein 10 for differentiating active tuberculosis from latent tuberculosis: A meta-analysis.

Authors:  Xia Qiu; Ying Tang; Rong Zou; Yan Zeng; Yan Yue; Wenxing Li; Yi Qu; Dezhi Mu
Journal:  Sci Rep       Date:  2019-08-06       Impact factor: 4.379

10.  High sensitivity and specificity of a 5-analyte protein and microRNA biosignature for identification of active tuberculosis.

Authors:  Jessica L Pedersen; Simone E Barry; Nilesh J Bokil; Magda Ellis; YuRong Yang; Guangyu Guan; Xiaolin Wang; Alen Faiz; Warwick J Britton; Bernadette M Saunders
Journal:  Clin Transl Immunology       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.